{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:23:47Z","timestamp":1783074227483,"version":"3.54.6"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["03-2022-2060"],"award-info":[{"award-number":["03-2022-2060"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2023-0109"],"award-info":[{"award-number":["6-2023-0109"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2023R1A2C3003782"],"award-info":[{"award-number":["2023R1A2C3003782"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.esmoop.2026.107730","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:30:01Z","timestamp":1780965001000},"page":"107730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal clinicogenetic criteria for post-operative re-irradiation in recurrent glioblastoma: KROG 21-02"],"prefix":"10.1016","volume":"11","author":[{"given":"S.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.I.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.H.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-7011","authenticated-orcid":false,"given":"J.H.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-O.","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-7549","authenticated-orcid":false,"given":"C.W.","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.A.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.107730_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107730_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.radonc.2017.02.014","article-title":"Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: a multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status","volume":"123","author":"Wee","year":"2017","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107730_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3349\/ymj.2022.0352","article-title":"Clinical outcomes of moderately hypofractionated concurrent chemoradiotherapy for newly diagnosed glioblastoma","volume":"64","author":"Kim","year":"2023","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.esmoop.2026.107730_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106006","article-title":"Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma","volume":"196","author":"Seyve","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib6","article-title":"Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma","volume":"3","author":"Schritz","year":"2021","journal-title":"Neuro Oncol Adv"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/nos273","article-title":"Standards of care for treatment of recurrent glioblastoma\u2014are we there yet?","volume":"15","author":"Weller","year":"2013","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/cancers13010047","article-title":"Recurrent glioblastoma: from molecular landscape to new treatment perspectives","volume":"13","author":"Birzu","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2026.107730_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jocn.2020.01.009","article-title":"Survival after reoperation for recurrent glioblastoma","volume":"73","author":"Woodroffe","year":"2020","journal-title":"J Clin Neurosci"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107730_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/02688690802182256","article-title":"\u2018Recurrent\u2019 glioblastoma multiforme, when should we reoperate?","volume":"22","author":"Barbagallo","year":"2008","journal-title":"Br J Neurosurg"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107730_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/neuonc\/nov326","article-title":"Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma\u2014results from the DIRECTOR trial","volume":"18","author":"Suchorska","year":"2016","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/neuonc\/nov145","article-title":"Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection","volume":"18","author":"Ringel","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107730_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3349\/ymj.2018.59.2.194","article-title":"Hypofractionated re-irradiation after maximal surgical resection for recurrent glioblastoma: therapeutic adequacy and its prognosticators of survival","volume":"59","author":"Lee","year":"2018","journal-title":"Yonsei Med J"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107730_bib14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG oncology\/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107730_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/6828396","article-title":"Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas","volume":"2018","author":"Zikou","year":"2018","journal-title":"Contrast Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijrobp.2017.08.038","article-title":"Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG Oncology\/Radiation Therapy Oncology Group trial 0525","volume":"100","author":"Shi","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2026.107730_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.esmoop.2026.107730_bib18","first-page":"1227","article-title":"Optimizing recurrent glioblastoma salvage treatment: a multicenter study integrating genetic biomarkers from the Korean Radiation Oncology Group (21-02)","volume":"10","author":"Kim","year":"2022","journal-title":"Neurosurgery"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107730_bib19","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107730_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11060-015-1893-z","article-title":"Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma","volume":"125","author":"Thomas","year":"2015","journal-title":"J Neuro Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107730_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jmri.26171","article-title":"Pseudoprogression of brain tumors","volume":"48","author":"Thust","year":"2018","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/nop\/npad063","article-title":"Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: a cohort study","volume":"11","author":"Blakstad","year":"2024","journal-title":"Neuro Oncol Pract"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107730_bib23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v18i3.755","article-title":"Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme","volume":"18","author":"Easaw","year":"2011","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107730_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3747\/co.22.2436","article-title":"Nonsurgical treatment of recurrent glioblastoma","volume":"22","author":"Gallego","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1016\/j.esmoop.2026.107730_bib25","first-page":"1","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.esmoop.2026.107730_bib26","article-title":"Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: target delineation, outcomes and patterns of recurrence","volume":"44","author":"Christ","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib27","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1038\/s41598-023-36290-2","article-title":"Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors","volume":"13","author":"You","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2026.107730_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11060-018-03059-x","article-title":"Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment: a multicenter study of the Radiation Oncology Italian Association (AIRO)","volume":"142","author":"Navarria","year":"2019","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.esmoop.2026.107730_bib29","first-page":"1","article-title":"Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers","author":"Straube","year":"2024","journal-title":"J Neuro Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107730_bib30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0092-8674(95)90214-7","article-title":"Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest","volume":"83","author":"Ouelle","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2026.107730_bib31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1010632309113","article-title":"The INK4A\/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth","volume":"51","author":"Ivanchuk","year":"2001","journal-title":"J Neuro Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib32","article-title":"Prognostic impact of CDKN2A\/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma","volume":"2","author":"Ma","year":"2020","journal-title":"Neuro Oncol Adv"},{"key":"10.1016\/j.esmoop.2026.107730_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11060-009-9967-4","article-title":"Different molecular patterns in glioblastoma multiforme subtypes upon recurrence","volume":"96","author":"Martinez","year":"2010","journal-title":"J Neuro Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2026.107730_bib34","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1158\/0008-5472.CAN-04-1337","article-title":"Genetic pathways to glioblastoma: a population-based study","volume":"64","author":"Ohgaki","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107730_bib35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00401-013-1163-0","article-title":"TERT promoter mutations in primary and secondary glioblastomas","volume":"126","author":"Nonoguchi","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107730_bib36","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/bjc.2014.538","article-title":"TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations","volume":"111","author":"Labussi\u00e8re","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12672-022-00590-2","article-title":"Impact of CDKN2A\/B, MTAP, and TERT genetic alterations on survival in IDH wild type glioblastomas","volume":"13","author":"Hsu","year":"2022","journal-title":"Discov Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107730_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/neuonc\/nou158","article-title":"TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas","volume":"17","author":"Simon","year":"2014","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107730_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3349\/ymj.2022.0414","article-title":"Selective inhibition of PI3K isoforms in brain tumors suppresses tumor growth by increasing radiosensitivity","volume":"64","author":"Seol","year":"2023","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.esmoop.2026.107730_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-014-0299-y","article-title":"Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients","volume":"9","author":"Niyazi","year":"2014","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107730_bib41","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.adro.2018.06.005","article-title":"Re-irradiation for malignant glioma: toward patient selection and defining treatment parameters for salvage","volume":"3","author":"Shen","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107730_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/nop\/npz017","article-title":"Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival","volume":"6","author":"Chapman","year":"2019","journal-title":"Neuro Oncol Pract"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:12:09Z","timestamp":1783073529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2059702926016728"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107730","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal clinicogenetic criteria for post-operative re-irradiation in recurrent glioblastoma: KROG 21-02","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107730"}}